PMID- 29864898
OWN - NLM
STAT- MEDLINE
DCOM- 20181015
LR  - 20190716
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 103
DP  - 2018 Jul
TI  - MiR-125b-5p suppressed the glycolysis of laryngeal squamous cell carcinoma by 
      down-regulating hexokinase-2.
PG  - 1194-1201
LID - S0753-3322(18)30513-4 [pii]
LID - 10.1016/j.biopha.2018.04.098 [doi]
AB  - Laryngeal squamous cell carcinoma (LSCC) is the most common form of laryngeal 
      carcinoma with poor prognosis. Exploring novel factors involved in the 
      progression of LSCC is quite necessary for understanding the mechanisms and 
      designing therapeutic strategies for LSCC. In this study, we showed that 
      miR-125b-5p was significantly down-regulated in LSCC tissues and cell lines. The 
      decreased expression of miR-125b-5p was associated with the tumor 
      differentiation, metastasis and high clinical stage of the LSCC patients. 
      Overexpression of miR-125b-5p suppressed the proliferation and induced apoptosis 
      of LSCC cells. Bioinformatics analysis predicted hexokinase-2 (HK2), an essential 
      enzyme involved in the glycolysis of cancer cells, as one of the downstream 
      targets of miR-125b-5p. Further molecular studies showed that highly expressed 
      miR-125b-5p bound the 3'-UTR of HK2 and decreased both the mRNA and protein 
      levels of HK2. Consistent with the function of HK2 in glycolytic metabolism, 
      overexpression of miR-125b-5p significantly suppressed the glucose consumption 
      and lactate production of LSCC cells. Notably, restoration the expression of HK2 
      attenuated the inhibitory effect of miR-125b-5p on the glycolysis of LSCC cells. 
      The inverse correlation between the expression of miR-125b-5p and HK2 in LSCC 
      tissues further supported the involvement of miR-125b-5p-HK2 axis in the 
      progression of LSCC. Collectively, these finding suggested the miR-125b-5p-HK2 
      pathway as a novel mechanism in regulating the glycolysis and progression of 
      LSCC.
CI  - Copyright (c) 2018 Elsevier Masson SAS. All rights reserved.
FAU - Hui, Lian
AU  - Hui L
AD  - Department of Otolaryngology, The First Hospital of China Medical University, No. 
      155 Nanjing Bei Street, Shenyang, 110001, China. Electronic address: 
      huilian3721@126.com.
FAU - Zhang, Jingru
AU  - Zhang J
AD  - Department of Otolaryngology, The First Hospital of China Medical University, No. 
      155 Nanjing Bei Street, Shenyang, 110001, China.
FAU - Guo, Xing
AU  - Guo X
AD  - Department of Otolaryngology, The First Hospital of China Medical University, No. 
      155 Nanjing Bei Street, Shenyang, 110001, China.
LA  - eng
PT  - Journal Article
DEP - 20180507
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (MIRN125 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - EC 2.7.1.1 (HK2 protein, human)
RN  - EC 2.7.1.1 (Hexokinase)
SB  - IM
MH  - Base Sequence
MH  - Carcinoma, Squamous Cell/*genetics/pathology
MH  - Cell Line, Tumor
MH  - Cell Proliferation/genetics
MH  - Down-Regulation/*genetics
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - *Glycolysis/genetics
MH  - Hexokinase/*genetics/metabolism
MH  - Humans
MH  - Laryngeal Neoplasms/*genetics/pathology
MH  - Male
MH  - MicroRNAs/genetics/*metabolism
MH  - Middle Aged
OTO - NOTNLM
OT  - Glycolysis
OT  - HK2
OT  - LSCC
OT  - miR-125b-5p
EDAT- 2018/06/06 06:00
MHDA- 2018/10/16 06:00
CRDT- 2018/06/06 06:00
PHST- 2018/01/23 00:00 [received]
PHST- 2018/04/13 00:00 [revised]
PHST- 2018/04/13 00:00 [accepted]
PHST- 2018/06/06 06:00 [entrez]
PHST- 2018/06/06 06:00 [pubmed]
PHST- 2018/10/16 06:00 [medline]
AID - S0753-3322(18)30513-4 [pii]
AID - 10.1016/j.biopha.2018.04.098 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2018 Jul;103:1194-1201. doi: 10.1016/j.biopha.2018.04.098. 
      Epub 2018 May 7.